Understanding healthcare providers' preferred attributes of pediatric pneumococcal conjugate vaccines in the United States
As higher-valent pneumococcal conjugate vaccines (PCVs) become available for pediatric populations in the US, it is important to understand healthcare provider (HCP) preferences for and acceptability of PCVs. US HCPs (pediatricians, family medicine physicians and advanced practitioners) completed an...
Gespeichert in:
| Veröffentlicht in: | Human vaccines & immunotherapeutics 2024-12, Vol.20 (1), p.2325745 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 2325745 |
| container_title | Human vaccines & immunotherapeutics |
| container_volume | 20 |
| creator | Mohanty, Salini Tsai, Jui-Hua Ning, Ning Martinez, Ana Verma, Rishi P. Heisen, Marieke Weaver, Jessica Feemster, Kristen A. Chun, Bianca Weiss, Thomas W. Schmier, Jordana K |
| description | As higher-valent pneumococcal conjugate vaccines (PCVs) become available for pediatric populations in the US, it is important to understand healthcare provider (HCP) preferences for and acceptability of PCVs. US HCPs (pediatricians, family medicine physicians and advanced practitioners) completed an online, cross-sectional survey between March and April 2023. HCPs were eligible if they recommended or prescribed vaccines to children age |
| doi_str_mv | 10.1080/21645515.2024.2325745 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_38566496</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_00e26ba049014e4383bf9cb8bf3d7a56</doaj_id><sourcerecordid>3031660593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c483t-60f9561a955f6da18ab2a24ac98e1f6bf12e2b8ab822ae5b29e1a8d20472bc203</originalsourceid><addsrcrecordid>eNp9Uk1vEzEQXSEQrUp_AmhvcEnwd9YnQBUflSpxgEjcrLF3NnG0sYPtDSq_HoekEb3gi0fvvXkz0rymeUnJnJKOvGVUCSmpnDPCxJxxJhdCPmkuD_hMSvHj6bmm8qK5znlD6ltUtVLPmwveSaWEVpfN72XoMeUCofdh1a4RxrJ2kLDdpbj3B-51LXHAlLBvoZTk7VQwt3Fod9h7qIBrdwGnbXTRORhbF8NmWkHBdg_O-VDFPrRlje0y-FJdvpVK5hfNswHGjNen_6pZfvr4_ebL7O7r59ubD3czJzpeZooMWioKWspB9UA7sAyYAKc7pIOyA2XIbEU7xgClZRopdD0jYsGsY4RfNbdH3z7CxuyS30K6NxG8-QvEtDKQincjGkKQKQtEaEIFCt5xO2hnOzvwfgFSVa93R6_dZLfYOwwlwfjI9DET_Nqs4t5QojXXVFaHNyeHFH9OmIvZ-uxwHCFgnLLhhFOliNS8SuVR6lLMud7gPIcSc8iBeciBOeTAnHJQ-179u-S56-HqVfD-KPBhiGkLv2Iae1PgfoxpSBCcr3v8f8YfB0vFZQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3031660593</pqid></control><display><type>article</type><title>Understanding healthcare providers' preferred attributes of pediatric pneumococcal conjugate vaccines in the United States</title><source>Taylor & Francis Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><creator>Mohanty, Salini ; Tsai, Jui-Hua ; Ning, Ning ; Martinez, Ana ; Verma, Rishi P. ; Heisen, Marieke ; Weaver, Jessica ; Feemster, Kristen A. ; Chun, Bianca ; Weiss, Thomas W. ; Schmier, Jordana K</creator><creatorcontrib>Mohanty, Salini ; Tsai, Jui-Hua ; Ning, Ning ; Martinez, Ana ; Verma, Rishi P. ; Heisen, Marieke ; Weaver, Jessica ; Feemster, Kristen A. ; Chun, Bianca ; Weiss, Thomas W. ; Schmier, Jordana K</creatorcontrib><description>As higher-valent pneumococcal conjugate vaccines (PCVs) become available for pediatric populations in the US, it is important to understand healthcare provider (HCP) preferences for and acceptability of PCVs. US HCPs (pediatricians, family medicine physicians and advanced practitioners) completed an online, cross-sectional survey between March and April 2023. HCPs were eligible if they recommended or prescribed vaccines to children age <24 months, spent ≥25% of their time in direct patient care, and had ≥2 y of experience in their profession. The survey included a discrete choice experiment (DCE) in which HCPs selected preferred options from different hypothetical vaccine profiles with systematic variation in the levels of five attributes. Relative attribute importance was quantified. Among 548 HCP respondents, the median age was 43.2 y, and the majority were male (57.9%) and practiced in urban areas (69.7%). DCE results showed that attributes with the greatest impact on HCP decision-making were 1) immune response for the shared serotypes covered by PCV13 (31.4%), 2) percent of invasive pneumococcal disease (IPD) covered by vaccine serotypes (21.3%), 3) acute otitis media (AOM) label indication (20.3%), 4) effectiveness against serotype 3 (17.6%), and 5) number of serotypes in the vaccine (9.5%). Among US HCPs, the most important attribute of PCVs was comparability of immune response for PCV13 shared serotypes, while the number of serotypes was least important. Findings suggest new PCVs eliciting high immune responses for serotypes that contribute substantially to IPD burden and maintaining immunogenicity against serotypes in existing PCVs are preferred by HCPs.</description><identifier>ISSN: 2164-5515</identifier><identifier>ISSN: 2164-554X</identifier><identifier>EISSN: 2164-554X</identifier><identifier>DOI: 10.1080/21645515.2024.2325745</identifier><identifier>PMID: 38566496</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Adult ; attitudes ; behaviors ; Child ; Child, Preschool ; Cross-Sectional Studies ; discrete choice experiment ; Female ; General Practitioners ; Heptavalent Pneumococcal Conjugate Vaccine ; Humans ; Infant ; knowledge ; Male ; pediatric vaccines ; Pneumococcal ; pneumococcal conjugate vaccines ; pneumococcal disease ; Pneumococcal Infections - prevention & control ; Pneumococcal Vaccines ; provider preferences ; Serogroup ; Streptococcus pneumoniae ; Survey ; United States ; Vaccines, Conjugate</subject><ispartof>Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2325745</ispartof><rights>2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024</rights><rights>2024 The Author(s). Published with license by Taylor & Francis Group, LLC. 2024 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c483t-60f9561a955f6da18ab2a24ac98e1f6bf12e2b8ab822ae5b29e1a8d20472bc203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.1080/21645515.2024.2325745$$EPDF$$P50$$Ginformaworld$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.1080/21645515.2024.2325745$$EHTML$$P50$$Ginformaworld$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,860,881,2096,27481,27903,27904,59119,59120</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38566496$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mohanty, Salini</creatorcontrib><creatorcontrib>Tsai, Jui-Hua</creatorcontrib><creatorcontrib>Ning, Ning</creatorcontrib><creatorcontrib>Martinez, Ana</creatorcontrib><creatorcontrib>Verma, Rishi P.</creatorcontrib><creatorcontrib>Heisen, Marieke</creatorcontrib><creatorcontrib>Weaver, Jessica</creatorcontrib><creatorcontrib>Feemster, Kristen A.</creatorcontrib><creatorcontrib>Chun, Bianca</creatorcontrib><creatorcontrib>Weiss, Thomas W.</creatorcontrib><creatorcontrib>Schmier, Jordana K</creatorcontrib><title>Understanding healthcare providers' preferred attributes of pediatric pneumococcal conjugate vaccines in the United States</title><title>Human vaccines & immunotherapeutics</title><addtitle>Hum Vaccin Immunother</addtitle><description>As higher-valent pneumococcal conjugate vaccines (PCVs) become available for pediatric populations in the US, it is important to understand healthcare provider (HCP) preferences for and acceptability of PCVs. US HCPs (pediatricians, family medicine physicians and advanced practitioners) completed an online, cross-sectional survey between March and April 2023. HCPs were eligible if they recommended or prescribed vaccines to children age <24 months, spent ≥25% of their time in direct patient care, and had ≥2 y of experience in their profession. The survey included a discrete choice experiment (DCE) in which HCPs selected preferred options from different hypothetical vaccine profiles with systematic variation in the levels of five attributes. Relative attribute importance was quantified. Among 548 HCP respondents, the median age was 43.2 y, and the majority were male (57.9%) and practiced in urban areas (69.7%). DCE results showed that attributes with the greatest impact on HCP decision-making were 1) immune response for the shared serotypes covered by PCV13 (31.4%), 2) percent of invasive pneumococcal disease (IPD) covered by vaccine serotypes (21.3%), 3) acute otitis media (AOM) label indication (20.3%), 4) effectiveness against serotype 3 (17.6%), and 5) number of serotypes in the vaccine (9.5%). Among US HCPs, the most important attribute of PCVs was comparability of immune response for PCV13 shared serotypes, while the number of serotypes was least important. Findings suggest new PCVs eliciting high immune responses for serotypes that contribute substantially to IPD burden and maintaining immunogenicity against serotypes in existing PCVs are preferred by HCPs.</description><subject>Adult</subject><subject>attitudes</subject><subject>behaviors</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Cross-Sectional Studies</subject><subject>discrete choice experiment</subject><subject>Female</subject><subject>General Practitioners</subject><subject>Heptavalent Pneumococcal Conjugate Vaccine</subject><subject>Humans</subject><subject>Infant</subject><subject>knowledge</subject><subject>Male</subject><subject>pediatric vaccines</subject><subject>Pneumococcal</subject><subject>pneumococcal conjugate vaccines</subject><subject>pneumococcal disease</subject><subject>Pneumococcal Infections - prevention & control</subject><subject>Pneumococcal Vaccines</subject><subject>provider preferences</subject><subject>Serogroup</subject><subject>Streptococcus pneumoniae</subject><subject>Survey</subject><subject>United States</subject><subject>Vaccines, Conjugate</subject><issn>2164-5515</issn><issn>2164-554X</issn><issn>2164-554X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>EIF</sourceid><sourceid>DOA</sourceid><recordid>eNp9Uk1vEzEQXSEQrUp_AmhvcEnwd9YnQBUflSpxgEjcrLF3NnG0sYPtDSq_HoekEb3gi0fvvXkz0rymeUnJnJKOvGVUCSmpnDPCxJxxJhdCPmkuD_hMSvHj6bmm8qK5znlD6ltUtVLPmwveSaWEVpfN72XoMeUCofdh1a4RxrJ2kLDdpbj3B-51LXHAlLBvoZTk7VQwt3Fod9h7qIBrdwGnbXTRORhbF8NmWkHBdg_O-VDFPrRlje0y-FJdvpVK5hfNswHGjNen_6pZfvr4_ebL7O7r59ubD3czJzpeZooMWioKWspB9UA7sAyYAKc7pIOyA2XIbEU7xgClZRopdD0jYsGsY4RfNbdH3z7CxuyS30K6NxG8-QvEtDKQincjGkKQKQtEaEIFCt5xO2hnOzvwfgFSVa93R6_dZLfYOwwlwfjI9DET_Nqs4t5QojXXVFaHNyeHFH9OmIvZ-uxwHCFgnLLhhFOliNS8SuVR6lLMud7gPIcSc8iBeciBOeTAnHJQ-179u-S56-HqVfD-KPBhiGkLv2Iae1PgfoxpSBCcr3v8f8YfB0vFZQ</recordid><startdate>20241231</startdate><enddate>20241231</enddate><creator>Mohanty, Salini</creator><creator>Tsai, Jui-Hua</creator><creator>Ning, Ning</creator><creator>Martinez, Ana</creator><creator>Verma, Rishi P.</creator><creator>Heisen, Marieke</creator><creator>Weaver, Jessica</creator><creator>Feemster, Kristen A.</creator><creator>Chun, Bianca</creator><creator>Weiss, Thomas W.</creator><creator>Schmier, Jordana K</creator><general>Taylor & Francis</general><general>Taylor & Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20241231</creationdate><title>Understanding healthcare providers' preferred attributes of pediatric pneumococcal conjugate vaccines in the United States</title><author>Mohanty, Salini ; Tsai, Jui-Hua ; Ning, Ning ; Martinez, Ana ; Verma, Rishi P. ; Heisen, Marieke ; Weaver, Jessica ; Feemster, Kristen A. ; Chun, Bianca ; Weiss, Thomas W. ; Schmier, Jordana K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c483t-60f9561a955f6da18ab2a24ac98e1f6bf12e2b8ab822ae5b29e1a8d20472bc203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>attitudes</topic><topic>behaviors</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Cross-Sectional Studies</topic><topic>discrete choice experiment</topic><topic>Female</topic><topic>General Practitioners</topic><topic>Heptavalent Pneumococcal Conjugate Vaccine</topic><topic>Humans</topic><topic>Infant</topic><topic>knowledge</topic><topic>Male</topic><topic>pediatric vaccines</topic><topic>Pneumococcal</topic><topic>pneumococcal conjugate vaccines</topic><topic>pneumococcal disease</topic><topic>Pneumococcal Infections - prevention & control</topic><topic>Pneumococcal Vaccines</topic><topic>provider preferences</topic><topic>Serogroup</topic><topic>Streptococcus pneumoniae</topic><topic>Survey</topic><topic>United States</topic><topic>Vaccines, Conjugate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mohanty, Salini</creatorcontrib><creatorcontrib>Tsai, Jui-Hua</creatorcontrib><creatorcontrib>Ning, Ning</creatorcontrib><creatorcontrib>Martinez, Ana</creatorcontrib><creatorcontrib>Verma, Rishi P.</creatorcontrib><creatorcontrib>Heisen, Marieke</creatorcontrib><creatorcontrib>Weaver, Jessica</creatorcontrib><creatorcontrib>Feemster, Kristen A.</creatorcontrib><creatorcontrib>Chun, Bianca</creatorcontrib><creatorcontrib>Weiss, Thomas W.</creatorcontrib><creatorcontrib>Schmier, Jordana K</creatorcontrib><collection>Taylor & Francis Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Human vaccines & immunotherapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mohanty, Salini</au><au>Tsai, Jui-Hua</au><au>Ning, Ning</au><au>Martinez, Ana</au><au>Verma, Rishi P.</au><au>Heisen, Marieke</au><au>Weaver, Jessica</au><au>Feemster, Kristen A.</au><au>Chun, Bianca</au><au>Weiss, Thomas W.</au><au>Schmier, Jordana K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Understanding healthcare providers' preferred attributes of pediatric pneumococcal conjugate vaccines in the United States</atitle><jtitle>Human vaccines & immunotherapeutics</jtitle><addtitle>Hum Vaccin Immunother</addtitle><date>2024-12-31</date><risdate>2024</risdate><volume>20</volume><issue>1</issue><spage>2325745</spage><pages>2325745-</pages><issn>2164-5515</issn><issn>2164-554X</issn><eissn>2164-554X</eissn><abstract>As higher-valent pneumococcal conjugate vaccines (PCVs) become available for pediatric populations in the US, it is important to understand healthcare provider (HCP) preferences for and acceptability of PCVs. US HCPs (pediatricians, family medicine physicians and advanced practitioners) completed an online, cross-sectional survey between March and April 2023. HCPs were eligible if they recommended or prescribed vaccines to children age <24 months, spent ≥25% of their time in direct patient care, and had ≥2 y of experience in their profession. The survey included a discrete choice experiment (DCE) in which HCPs selected preferred options from different hypothetical vaccine profiles with systematic variation in the levels of five attributes. Relative attribute importance was quantified. Among 548 HCP respondents, the median age was 43.2 y, and the majority were male (57.9%) and practiced in urban areas (69.7%). DCE results showed that attributes with the greatest impact on HCP decision-making were 1) immune response for the shared serotypes covered by PCV13 (31.4%), 2) percent of invasive pneumococcal disease (IPD) covered by vaccine serotypes (21.3%), 3) acute otitis media (AOM) label indication (20.3%), 4) effectiveness against serotype 3 (17.6%), and 5) number of serotypes in the vaccine (9.5%). Among US HCPs, the most important attribute of PCVs was comparability of immune response for PCV13 shared serotypes, while the number of serotypes was least important. Findings suggest new PCVs eliciting high immune responses for serotypes that contribute substantially to IPD burden and maintaining immunogenicity against serotypes in existing PCVs are preferred by HCPs.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>38566496</pmid><doi>10.1080/21645515.2024.2325745</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2164-5515 |
| ispartof | Human vaccines & immunotherapeutics, 2024-12, Vol.20 (1), p.2325745 |
| issn | 2164-5515 2164-554X 2164-554X |
| language | eng |
| recordid | cdi_pubmed_primary_38566496 |
| source | Taylor & Francis Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Alma/SFX Local Collection |
| subjects | Adult attitudes behaviors Child Child, Preschool Cross-Sectional Studies discrete choice experiment Female General Practitioners Heptavalent Pneumococcal Conjugate Vaccine Humans Infant knowledge Male pediatric vaccines Pneumococcal pneumococcal conjugate vaccines pneumococcal disease Pneumococcal Infections - prevention & control Pneumococcal Vaccines provider preferences Serogroup Streptococcus pneumoniae Survey United States Vaccines, Conjugate |
| title | Understanding healthcare providers' preferred attributes of pediatric pneumococcal conjugate vaccines in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T19%3A23%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Understanding%20healthcare%20providers'%20preferred%20attributes%20of%20pediatric%20pneumococcal%20conjugate%20vaccines%20in%20the%20United%20States&rft.jtitle=Human%20vaccines%20&%20immunotherapeutics&rft.au=Mohanty,%20Salini&rft.date=2024-12-31&rft.volume=20&rft.issue=1&rft.spage=2325745&rft.pages=2325745-&rft.issn=2164-5515&rft.eissn=2164-554X&rft_id=info:doi/10.1080/21645515.2024.2325745&rft_dat=%3Cproquest_pubme%3E3031660593%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3031660593&rft_id=info:pmid/38566496&rft_doaj_id=oai_doaj_org_article_00e26ba049014e4383bf9cb8bf3d7a56&rfr_iscdi=true |